tetano
Editor, Senior Moderator
Wien Klin Wochenschr
. 2021 Apr 27.
doi: 10.1007/s00508-021-01867-2. Online ahead of print.
Attenuation of COVID-19-induced cytokine storm in a young male patient with severe respiratory and neurological symptoms
Christian Muschitz[SUP] 1 [/SUP], Anita Trummert[SUP] 2 [/SUP], Theresa Berent[SUP] 3 [/SUP], Norbert Laimer[SUP] 3 [/SUP], Lukas Knoblich[SUP] 3 [/SUP], Gerd Bodlaj[SUP] 3 [/SUP], Alexander Krainer[SUP] 4 [/SUP], Christoph Linder[SUP] 2 [/SUP], Heinrich Resch[SUP] 3 5 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), produces protean manifestations and causes indiscriminate havoc in multiple organ systems. This rapid and vast production of proinflammatory cytokines contributes to a condition termed cytokine storm. A 35-year-old, otherwise healthy, employed, male patient was tested positive for COVID-19. He was admitted to the hospital on disease day 10 due to retarded verbal reactions and progressive delirium. On account of these conditions and the need for noninvasive/invasive ventilation, a combination treatment with baricitinib and remdesivir in conjunction with standard of care was initiated. The cytokine storm was rapidly blocked, leading to a vast pulmonary recovery with retarded recovery of the central nervous system. We conclude that the rapid blockade of the COVID-19-induced cytokine storm should be considered of avail as a principle of careful decision-making for effective recovery.
Keywords: Baricitinib; COVID-19; Cytokine storm; Inflammation; Remdesivir.
. 2021 Apr 27.
doi: 10.1007/s00508-021-01867-2. Online ahead of print.
Attenuation of COVID-19-induced cytokine storm in a young male patient with severe respiratory and neurological symptoms
Christian Muschitz[SUP] 1 [/SUP], Anita Trummert[SUP] 2 [/SUP], Theresa Berent[SUP] 3 [/SUP], Norbert Laimer[SUP] 3 [/SUP], Lukas Knoblich[SUP] 3 [/SUP], Gerd Bodlaj[SUP] 3 [/SUP], Alexander Krainer[SUP] 4 [/SUP], Christoph Linder[SUP] 2 [/SUP], Heinrich Resch[SUP] 3 5 [/SUP]
Affiliations
- PMID: 33905029
- DOI: 10.1007/s00508-021-01867-2
Abstract
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), produces protean manifestations and causes indiscriminate havoc in multiple organ systems. This rapid and vast production of proinflammatory cytokines contributes to a condition termed cytokine storm. A 35-year-old, otherwise healthy, employed, male patient was tested positive for COVID-19. He was admitted to the hospital on disease day 10 due to retarded verbal reactions and progressive delirium. On account of these conditions and the need for noninvasive/invasive ventilation, a combination treatment with baricitinib and remdesivir in conjunction with standard of care was initiated. The cytokine storm was rapidly blocked, leading to a vast pulmonary recovery with retarded recovery of the central nervous system. We conclude that the rapid blockade of the COVID-19-induced cytokine storm should be considered of avail as a principle of careful decision-making for effective recovery.
Keywords: Baricitinib; COVID-19; Cytokine storm; Inflammation; Remdesivir.